AVITA Medical, Inc. (ASX:AVH)

Market Cap	225.40M
Revenue (ttm)	114.22M
Net Income (ttm)	-78.66M
Shares Out	n/a
EPS (ttm)	-3.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450,585
Average Volume	967,307
Open	1.470
Previous Close	1.450
Day's Range	1.470 - 1.495
52-Week Range	1.330 - 4.520
Beta	1.63
RSI	41.37
Earnings Date	Aug 7, 2025

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2020
• Employees: 260
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVH

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Financial numbers in USD